Litcius/Paper detail

Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches

Cena Aram, Parsa Alijanizadeh, Kiarash Saleki, Leila Karami

2024Biochemistry and Biophysics Reports32 citationsDOIOpen Access PDF

Abstract

I position of the pET-28a (+) vector, and simulating the agarose gel revealed the existence of the inserted gene in the cloned plasmid with SARS vaccine (SARSV) construct, which has a 6565 bp in length overall. In terms of cytokines/IgG response, immunological simulation revealed a strong immune response. The stabilized vaccine showed strong interactions with TLR3/4, according to Molecular Dynamics Simulation (MDS) analysis. The present ancestral vaccine targets common sequences which seem to be valuable targets even for the new variant SARS-CoV-2.

Topics & Concepts

EpitopeVirologyCoronavirusBiologyPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Spike ProteinImmune systemVirusAntibodyComputational biologyCoronavirus disease 2019 (COVID-19)GeneticsMedicineDiseasePathologyInfectious disease (medical specialty)vaccines and immunoinformatics approachesSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responses
Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches | Litcius